Rosiglitazone maleate (BRL 49653C)是一种有效的选择性PPARγ激活剂,同时也是TRP通道调节剂,可抑制TRPM2/3并激活TRPC5。
|
英文别名 (English Synonym) |
Rosiglitazone maleate |
|
中文名称 (Chinese Name) |
马来酸罗格列酮 |
|
靶点 (Target) |
PPAR |
|
通路 (Pathway) |
Protease/Metabolic Enzyme |
|
CAS号 (CAS NO.) |
155141-29-0 |
|
分子式 (Formula) |
C18H19N3O3S·C4H4O4 |
|
分子量 (Molecular Weight) |
473.5 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Thouennon E, Cheng Y, Falahatian V, Cawley NX, Loh YP. Rosiglitazone-activated PPARγ induces neurotrophic factor-α1 transcription contributing to neuroprotection. J Neurochem. 2015 Aug,134(3):463-70. doi: 10.1111/jnc.13152. Epub 2015 Jun 1. PMID: 25940785, PMCID: PMC4496294.[2]Ateyya H, Nader MA, El-Sherbeeny NA. Beneficial effects of rosiglitazone and losartan combination in diabetic rats. Can J Physiol Pharmacol. 2018 Mar,96(3):215-220. doi: 10.1139/cjpp-2017-0332. Epub 2017 Sep 11. PMID: 28892640.
